COMP <GO>
SLGN vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Silgan Holdings Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: SLGN 6
— TMO 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $39.49 (+4.11%) • MKT CAP: $4.17B
balance-sheet
1.97
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLGN VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SLGN | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 17.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.70% | 9.30% | -3.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 11.1x | 30.4x | -19.30 | SLGN | /valuation <GO> |
| Free Cash Flow Yield | 10.13% | 2.40% | +7.73 | SLGN | /fcf-yield <GO> |
| Operating Margin | 5.40% | 17.40% | -12.00 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.40% | 15.10% | -10.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 10.70% | 3.90% | +6.80 | SLGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.06% | 0.24% | +1.82 | SLGN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.97 | 4.50 | -2.53 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.8 | 62.9 | -6.10 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.94 | +0.10 | SLGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 36.3x | -22.80 | SLGN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.17B | $262.22B | -$258.04B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SLGN REV | TMO REV | SLGN GROSS % | TMO GROSS % | SLGN FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.48B | $44.56B | 17.7% | — | $422.7M | $6.29B |
| FY 2024 | $5.85B | $42.88B | 17.3% | — | $459.1M | $7.27B |
| FY 2023 | $5.99B | $42.86B | — | — | $213.1M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLGN // BETA 1.04
TMO // BETA 0.94